TBL1XR1, IRF4, TP53, FOXO1, KMT2C (MLL3), CCND3, NFKBIZ, and STAT6, were potential candidate targets to overcome drug resistance in DLBCL [5, 6]. Here, KMT2C is linked to diffuse large B-cell lymphoma.